Drug prices. What two other words generate more public passion, political interest and regulatory heartburn in the pharmaceutical industry?
All those things were on display in July 2014 when Gilead Sciences Inc. received a letter from U.S. Senators Ron Wyden, D-Ore., and Chuck Grassley, R-Iowa, wanting to know why the company’s blockbuster Hepatitis C drug, Sovaldi, was priced at $1,000 a pill in the United States. The senators warned publicly that the price tag could cost Medicare and Medicaid billions more annually, even as the drug was being sold much more cheaply in other countries.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
